PURPOSE: The aim of the present study was to examine the effect of neoadjuvant chemoradiation on tumor epidermal growth factor receptor (EGFR) expression in patients with locally advanced rectal adenocarcinoma. PATIENTS AND METHODS: A total of 53 patients with rectal adenocarcinoma (clinical stages II and III) were studied. Neoadjuvant treatment consisted of 50.4 Gy/28 fractions external radiation with concomitant continuous 5-fluorouracil. Surgical resection was performed 4-6 weeks after the chemoradiation. EGFR expression in the pretreatment biopsies and in the resected specimens was assessed with immunohistochemistry. RESULTS: Patients with an increase of EGFR expression during chemoradiation had significantly shorter disease-free survival (DFS; p = 0.003) and overall survival (OS; p = 0.005) compared to patients with either no change or decrease in EGFR expression. The 5-year DFS in patients with increased EGFR expression was only 29% compared to 61% in patients without an increase of EGFR expression. Similarly, the 5-year OS of the patients with increased EGFR expression was 29% compared to 66% in patients without an increase of EGFR expression. All recurrences in patients who had an increase of EGFR expression occurred within the first 2 years after the treatment. The increase in EGFR expression was the only significant predictor of DFS (p = 0.007) and OS (p = 0.04) using multivariate Cox regression analysis. CONCLUSION: An increase of EGFR expression during chemoradiation may be associated with significantly shorter DFS and OS. The increase of EGFR could identify a population of patients in whom the effect of the treatment with anti-EGFR therapy should be studied.
PURPOSE: The aim of the present study was to examine the effect of neoadjuvant chemoradiation on tumorepidermal growth factor receptor (EGFR) expression in patients with locally advanced rectal adenocarcinoma. PATIENTS AND METHODS: A total of 53 patients with rectal adenocarcinoma (clinical stages II and III) were studied. Neoadjuvant treatment consisted of 50.4 Gy/28 fractions external radiation with concomitant continuous 5-fluorouracil. Surgical resection was performed 4-6 weeks after the chemoradiation. EGFR expression in the pretreatment biopsies and in the resected specimens was assessed with immunohistochemistry. RESULTS:Patients with an increase of EGFR expression during chemoradiation had significantly shorter disease-free survival (DFS; p = 0.003) and overall survival (OS; p = 0.005) compared to patients with either no change or decrease in EGFR expression. The 5-year DFS in patients with increased EGFR expression was only 29% compared to 61% in patients without an increase of EGFR expression. Similarly, the 5-year OS of the patients with increased EGFR expression was 29% compared to 66% in patients without an increase of EGFR expression. All recurrences in patients who had an increase of EGFR expression occurred within the first 2 years after the treatment. The increase in EGFR expression was the only significant predictor of DFS (p = 0.007) and OS (p = 0.04) using multivariate Cox regression analysis. CONCLUSION: An increase of EGFR expression during chemoradiation may be associated with significantly shorter DFS and OS. The increase of EGFR could identify a population of patients in whom the effect of the treatment with anti-EGFR therapy should be studied.
Authors: Marc Peeters; Timothy Jay Price; Andrés Cervantes; Alberto F Sobrero; Michel Ducreux; Yevhen Hotko; Thierry André; Emily Chan; Florian Lordick; Cornelis J A Punt; Andrew H Strickland; Gregory Wilson; Tudor-Eliade Ciuleanu; Laslo Roman; Eric Van Cutsem; Valentina Tzekova; Simon Collins; Kelly S Oliner; Alan Rong; Jennifer Gansert Journal: J Clin Oncol Date: 2010-10-04 Impact factor: 44.544
Authors: J-P Machiels; C Sempoux; P Scalliet; J-C Coche; Y Humblet; E Van Cutsem; J Kerger; J-L Canon; M Peeters; S Aydin; S Laurent; A Kartheuser; B Coster; S Roels; J-F Daisne; B Honhon; L Duck; C Kirkove; M-A Bonny; K Haustermans Journal: Ann Oncol Date: 2007-01-05 Impact factor: 32.976
Authors: R K Schmidt-Ullrich; R B Mikkelsen; P Dent; D G Todd; K Valerie; B D Kavanagh; J N Contessa; W K Rorrer; P B Chen Journal: Oncogene Date: 1997-09-04 Impact factor: 9.867
Authors: C Pinto; F Di Fabio; E Maiello; S Pini; T Latiano; C Aschele; C Garufi; A Bochicchio; G Rosati; G Aprile; S Giaquinta; V Torri; A Bardelli; M Gion; A Martoni Journal: Ann Oncol Date: 2011-03-08 Impact factor: 32.976
Authors: David Azria; Frederic Bibeau; Nicolas Barbier; Abderrahim Zouhair; Claire Lemanski; Philippe Rouanet; Marc Ychou; Pierre Senesse; Mahmut Ozsahin; André Pèlegrin; Jean-Bernard Dubois; Simon Thèzenas Journal: BMC Cancer Date: 2005-06-20 Impact factor: 4.430
Authors: Miroslav Hodek; Igor Sirák; Alexander Ferko; Július Örhalmi; Eva Hovorková; Dimitar Hadži Nikolov; Petr Paluska; Jindřich Kopecký; Jiří Petera; Milan Vošmik Journal: Strahlenther Onkol Date: 2016-06-06 Impact factor: 3.621
Authors: Igor Richter; Josef Dvořák; Marek Urbanec; Antonin Bluml; Eva Čermáková; Jiří Bartoš; Jiří Petera Journal: Contemp Oncol (Pozn) Date: 2015-03-26